10-Q: Tourmaline Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

Tourmaline Bio reports a net loss of $20.2 million for the third quarter of 2024, alongside significant increases in research and development spending.

Summary

• Tourmaline Bio reported a net loss of $20.2 million for the three months ended September 30, 2024, compared to a net loss of $5.6 million for the same period in 2023.
• The company's research and development expenses increased significantly to $19.3 million in the third quarter of 2024, up from $3.8 million in the third quarter of 2023.
• General and administrative expenses also rose to $5.1 million in the third quarter of 2024, compared to $2.9 million in the same period of 2023.
• Other income, net, which includes interest and investment income, increased to $4.3 million in the third quarter of 2024, up from $1.1 million in the third quarter of 2023.
• For the nine months ended September 30, 2024, the company's net loss was $51.0 million, compared to a net loss of $29.2 million for the same period in 2023.
• As of September 30, 2024, Tourmaline Bio had cash, cash equivalents, and investments totaling $314.4 million.
• The company expects its existing cash, cash equivalents, and investments to fund operations for at least 12 months from November 7, 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has a strong cash position and is progressing with clinical trials, the significant increase in net loss and identified material weaknesses in internal controls are concerning. The company is also reliant on third parties for manufacturing and clinical trials, which introduces risk. The sentiment is neutral to slightly negative.

Positives

• The company has a strong cash position of $314.4 million, which is expected to fund operations for at least 12 months.
• The company is progressing with clinical trials for pacibekitug in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD).
• The company has reached alignment with the FDA on the ASCVD clinical development program.
• The company has initiated a Phase 2 trial of pacibekitug in patients with chronic kidney disease and elevated hs-CRP.
• The company completed a successful public offering in January 2024, raising significant capital.

Negatives

• The company experienced a significant increase in net loss, from $5.6 million in Q3 2023 to $20.2 million in Q3 2024.
• Research and development expenses have increased substantially, indicating higher spending on clinical trials and development.
• The company has an accumulated deficit of $113.0 million as of September 30, 2024.
• The company has identified material weaknesses in its internal control over financial reporting.

Risks

• The company is subject to risks common to companies in the biotechnology industry, including new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing.
• The company's product candidates will require significant additional research and development efforts, including extensive clinical testing and regulatory approval, prior to commercialization.
• The company relies completely on contract development and manufacturing organizations (CDMOs) for the manufacture and testing of pacibekitug and any potential future product candidates under cGMP, and is subject to many manufacturing risks.
• The company may not be able to obtain and maintain the relationships with third parties that are necessary to develop, commercialize, and manufacture pacibekitug and any potential future product candidates.
• The company may not be able to access sufficient capital on acceptable terms, if at all, and, as a result, may be required to delay, scale back or discontinue development of such product candidates or other operations.
• The company has identified material weaknesses in its internal control over financial reporting, which could lead to inaccurate financial reporting.

Future Outlook

The company expects its existing cash, cash equivalents and investments will enable it to fund its expected operating expenses and capital expenditure requirements for at least 12 months from November 7, 2024. The company expects to finance its future cash needs through a combination of equity or debt financings, collaborations, licensing arrangements and strategic alliances.

Management Comments

• The company expects to report topline data from the spiriTED trial in the second half of 2025.
• The company expects to commence a pivotal Phase 3 trial of pacibekitug in first-line TED in the second half of 2024.
• The company expects to report topline data from the TRANQUILITY trial in the first half of 2025.

Industry Context

The company is developing pacibekitug, a monoclonal antibody targeting IL-6, a key inflammatory cytokine. This is relevant as the anti-IL-6 and anti-IL-6 receptor antibody class has over two decades of clinical and commercial experience treating autoimmune and inflammatory diseases, with four approved antibodies generating over $3.5 billion in global sales in 2023. The company is also exploring pacibekitug's potential in cardiovascular inflammation, which is a growing area of interest in the pharmaceutical industry.

Comparison to Industry Standards

• The company's focus on IL-6 inhibition aligns with a well-established class of therapeutics, with several approved drugs like Actemra (tocilizumab) and Kevzara (sarilumab) demonstrating efficacy in autoimmune and inflammatory conditions.
• The company's approach to thyroid eye disease (TED) is notable, as there is currently only one approved therapy (Tepezza) specifically for this condition, and the company is exploring a different mechanism of action (IL-6 inhibition) compared to Tepezza (IGF-1R inhibition).
• The company's entry into the cardiovascular inflammation space is also significant, as there is growing interest in targeting inflammation to reduce cardiovascular risk, with multiple Phase 3 trials of IL-6 blockade ongoing by other companies.
• The company's stated goal of achieving substantial IL-6 pathway suppression with relatively low amounts of drug exposure, potentially enabling delivery in a convenient, low volume, infrequently administered, subcutaneous injection, is a key differentiator compared to existing therapies that often require intravenous administration.
• The company's financial position, with $314.4 million in cash and investments, is relatively strong compared to other clinical-stage biotech companies, providing a runway to fund ongoing clinical trials and development activities.

Legal Proceedings

• From time to time, the Company may become subject to legal proceedings, claims and litigation arising in the ordinary course of business.
• The company believes there are currently no pending legal proceedings to which it or its property are subject that could have a material adverse effect on its financial position, results of operations or cash flows.

Related Party Transactions

• In May 2023, an advisor affiliated with Fourth Avenue FF Opportunities LP Series Z, previously a beneficial owner of the Companys outstanding capital stock, exercised stock options to purchase 75,782 shares of the Companys common stock for $0.13 per share.
• The Company subsequently repurchased the shares from the advisor at $2.76 per share, equivalent to fair value as of the repurchase date, for an aggregate purchase price of $0.2 million.
• Fourth Avenue FF Opportunities LP Series Z then purchased the shares from the Company at the same amount $2.76 per share for an aggregate purchase price of $0.2 million.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and the identified material weaknesses in internal controls.
• Employees may be affected by the company's growth and potential changes in operations.
• Customers (potential patients) may be impacted by the progress of clinical trials and the potential availability of new therapies.
• Suppliers and creditors may be affected by the company's financial performance and ability to meet its obligations.

Next Steps

• The company expects to report topline data from the spiriTED trial in the second half of 2025.
• The company expects to commence a pivotal Phase 3 trial of pacibekitug in first-line TED in the second half of 2024.
• The company expects to report topline data from the TRANQUILITY trial in the first half of 2025.

Key Dates

Keywords

pacibekitug, TOUR006, thyroid eye disease, TED, atherosclerotic cardiovascular disease, ASCVD, clinical trials, biotechnology, monoclonal antibody, interleukin-6, IL-6, research and development, financial results, regulatory approval